ARID5B

Across TCGA pan-cancer cohorts, ARID5B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARID5B data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ARID5B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ARID5B expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, LUSC, and PRAD are the cancer types where ARID5B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.763	0.627	.004	30	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	24	view →
PRAD	DFS	Median	All	0.176	0.888	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
STAD	DFS	Median	All	0.878	0.388	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARID5B–UCEC (DFS)

Open the UCEC breakdown →